{
    "ticker": "XBJL",
    "name": "Xenon Biopharma, Inc.",
    "description": "Xenon Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with rare diseases and neurological disorders. Founded in 1996, Xenon leverages its proprietary drug development platform and deep expertise in genetics to discover and advance new treatments. The company is known for its commitment to addressing unmet medical needs through the development of novel medicines that target specific genetic mutations. Xenon's lead product candidates include XEN490, an innovative treatment for various forms of epilepsy, and XEN901, a potential therapy for patients with pain and other neurological conditions. The company\u2019s research is guided by a team of experienced scientists and clinicians who are dedicated to transforming the lives of patients. Xenon aims to harness the power of precision medicine to create therapies that are not only effective but also tailored to the genetic profiles of patients. As Xenon continues to advance its pipeline, the company is also focused on building partnerships within the biopharmaceutical industry to enhance its research capabilities and expedite the delivery of new therapies to those in need.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Vancouver, British Columbia, Canada",
    "founded": "1996",
    "website": "https://www.xenon-pharma.com",
    "ceo": "Simon M. Pimstone",
    "social_media": {
        "twitter": "https://twitter.com/XenonPharma",
        "linkedin": "https://www.linkedin.com/company/xenon-pharmaceuticals/"
    },
    "investor_relations": "https://investors.xenon-pharma.com",
    "key_executives": [
        {
            "name": "Simon M. Pimstone",
            "position": "CEO"
        },
        {
            "name": "Eric L. K. Kelsey",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Clinical Development",
            "products": [
                "XEN901",
                "XEN490"
            ]
        }
    ],
    "seo": {
        "meta_title": "Xenon Biopharma, Inc. | Innovative Therapies for Rare Diseases",
        "meta_description": "Learn about Xenon Biopharma, Inc., a leader in the development of therapies for rare diseases and neurological disorders. Discover their innovative pipeline and commitment to precision medicine.",
        "keywords": [
            "Xenon Biopharma",
            "Rare Diseases",
            "Neurological Disorders",
            "XEN901",
            "XEN490",
            "Biopharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is Xenon Biopharma known for?",
            "answer": "Xenon Biopharma is known for developing innovative therapies for rare diseases and neurological disorders."
        },
        {
            "question": "Who is the CEO of Xenon Biopharma?",
            "answer": "Simon M. Pimstone is the CEO of Xenon Biopharma, Inc."
        },
        {
            "question": "Where is Xenon Biopharma headquartered?",
            "answer": "Xenon Biopharma is headquartered in Vancouver, British Columbia, Canada."
        },
        {
            "question": "What are Xenon Biopharma's main products?",
            "answer": "Xenon Biopharma's main products include XEN901 and XEN490."
        },
        {
            "question": "When was Xenon Biopharma founded?",
            "answer": "Xenon Biopharma was founded in 1996."
        }
    ],
    "competitors": [
        "AVTX",
        "CRSP",
        "SAGE",
        "SGMO"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "JNJ",
        "PFE"
    ]
}